Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody
Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children
Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry
Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial
